Biosilu Healthcare is actively pursuing collaborations with western biopharmaceutical companies seeking to make their innovative products available to patients in Asia / China.
We focus on development products, preferentially with a clinical-proof-of-concept in areas of high medical need in Asia. These areas include: infectious diseases, fertility, tumor indications and other rare diseases with high medical need among Asian patients.
The combination of a continued strong market demand with increasing efforts by Chinese regulatory authorities (CFDA) to accelerate the approval timelines also for foreign drugs while ensuring global standards in terms of quality and transparency of clinical development makes it more attractive for foreign innovation-based companies to enter the Chinese market early.
Klaus Wilgenbus CEO Biosilu Healthcare